San Diego-centered Viking Therapeutics marked itself as a serious competitor inside the weight loss drug industry in February after revealing promising info from the mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when offered being a weekly injection and in March the company unveiled